medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2010, Número 2

<< Anterior Siguiente >>

Rev Invest Clin 2010; 62 (2)


Antiplaquetarios en la prevención del infarto cerebral o isquemia cerebral transitoria aterotrombótica

Barinagarrementeria F, Arauz A, Ruiz-Sandoval JL, Cantú C, Leyva A, Murillo L, Villarreal J,Vargas RD, Alegría MA, Merino JG, Romano J

Idioma: Español
Referencias bibliográficas: 17
Paginas: 135-140
Archivo PDF: 73.20 Kb.


FRAGMENTO

La isquemia cerebral (IC) se debe frecuentemente a la oclusión arterial de los vasos sanguíneos intra o extracraneales por un trombo o émbolo. El sitio de lesión inicial con mayor frecuencia se localiza en los vasos extracraneales, frecuentemente la arteria carótida interna y la causa más común es la enfermedad ateroesclerosa. Estos trombos o émbolos están constituidos esencialmente por material fibrinoplaquetario.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Miner J, Hoffhines A. The discovery of aspirin’s antithrombotic effects. Tex Heart Inst J 2007; 34: 179-86.

  2. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Antithrombotic Trialists’ Collaboration. BMJ 2002; 324: 71-86.

  3. Lievre M, Cucherat M. Aspirin in the secondary prevention of cardiovascular disease: an update of the APTC meta-analysis. Fundam Clin Pharmacol. 2009.

  4. CAPRIE Steering Committee. A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 329-39.

  5. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001; 345: 494-502.

  6. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo- controlled trial. Lancet 2004; 364: 331-7.

  7. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, et al. Charisma Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354: 1706-17.

  8. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study: 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1-13.

  9. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A; ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665-73.

  10. Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39: 1358-63.

  11. Sacco RL, Diener H-C, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, et al. Aspirin and extended release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359:1238-51.

  12. Huang Y, Cheng Y, Wu J, Li Y, Xu E, Hong Z, et al. Cilostazol versus Aspirin for Secondary Ischaemic Stroke Prevention cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7: 469-70.

  13. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67.

  14. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78.

  15. Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, Coste J. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001; 345: 1740-6.

  16. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP, PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002; 105: 2625-31.

  17. Almekhlafi MA, Wilton SB, Rabi DM, Ghali WA, Lorenzetti DL, Hill MD. Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology. 2009; 73: 89-97.




2020     |     www.medigraphic.com